Innovative Health Initiative launches wide-ranging new funding round
The Innovative Health Initiative (IHI) has launched two new calls for proposals, IHI calls 6 and 7, addressing a wide range of challenges in health research and innovation. Close on EUR 120 million in funding from IHI is available through IHI calls 6 and 7; these funds come from Horizon Europe, the EU’s research and innovation funding programme. IHI’s industry partners and (where relevant) contributing partners are expected to contribute an equivalent amount.
Notes to editors
More information on the new calls can be found on the IHI website.
IHI call 6 (two-stage call)
- Deadline for short proposals: 16 April 2024
- More information and details of how to apply: www.ihi.europa.eu/apply-funding/ihi-call-6
IHI call 7 (single-stage call)
- Deadline for full proposals: 22 May 2024
- More information and details of how to apply: www.ihi.europa.eu/apply-funding/ihi-call-7
About IHI
The Innovative Health Initiative (IHI) aims to translate health research and innovation into real benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research. Health research and care increasingly involve diverse sectors. By supporting projects that bring these sectors together, IHI will pave the way for a more integrated approach to health care, covering prevention, diagnosis, treatment, and disease management.
IHI is a partnership between the European Union and European industry associations representing the pharmaceutical, medical technology, biotechnology, digital health and vaccine industries, namely COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe. IHI’s total budget is EUR 2.4 billion. Half of this comes from Horizon Europe, the EU’s research and innovation programme. The IHI industry partners have committed EUR 1 billion to IHI, and a further EUR 200 million can be committed by other organisations that decide to become Contributing Partners.
IHI builds on the successes of the Innovative Medicines Initiative (IMI), and the IHI Programme Office continues to manage the IMI project portfolio.